SimBioSys and Mayo Clinic collaborate on AI-powered precision medicine for cancer

SimBioSys, a TechBio company specialising in spatial biophysics with AI and biophysical modelling for precision medicine in cancer, has entered a strategic collaboration with Mayo Clinic. The collaboration aims to develop cloud-based clinical software tools for early-stage breast cancer patients, covering individualised surgical planning, treatment, drug selection, and risk stratification. 

The goal is to tailor treatment plans based on spatial biophysical insights, improving patient outcomes while preserving quality of life. Mayo Clinic physicians Judy C. Boughey and Matthew Goetz are part of the SimBioSys clinical advisory team, supporting the development and validation of these clinical software tools using data from the Mayo Clinic-led BEAUTY clinical trial.

SimBioSys is developing a cloud-based platform, TumorSight, as a medical device for treatment planning. The platform's first product, currently under FDA review, creates a custom 3D digital model of a patient's breast cancer using standard-of-care DCE-MRI imaging. This tool provides surgical oncologists with clear 3D visualisations, aiding in surgical planning and patient consultations. 

SimBioSys emphasises its approach of complementing existing precision medicine techniques by relying on readily available datasets like imaging. The collaboration with Mayo Clinic, a Comprehensive Cancer Center, is expected to bring innovative technology to patients, potentially advancing the standard of care in breast cancer treatment. Mayo Clinic holds a financial interest in the technology, with revenue directed toward its not-for-profit mission in patient care, education, and research.